Abu Dhabi Stem Cells Partners with Milteni to Develop CAR-T Therapies

The Abu Dhabi Stem Cell Center and German company "Miltini Biomedicine" signed an agreement to enhance the development and manufacturing of genetically modified immune cell therapies "CAR-T" in the UAE. The goal is to establish the first regional center offering this treatment locally and to explore its potential in treating various serious diseases, including cancers and autoimmune disorders. The agreement allows the center to develop and produce "CAR-T" therapies using Miltini's technical and research expertise, reducing the need for patients to travel abroad for treatment. "CAR-T" therapy involves modifying immune cells to target specific cells, and has proven effective in treating certain types of blood cancers, with ongoing research aimed at expanding its use to other diseases. The collaboration aims to expand the UAE’s capabilities in this field and translate scientific knowledge into tangible therapeutic results, focusing on improving treatment options and enabling broader application of the technology.

articleDetails.fontSize.sizeحجم النص

تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي

عرض المقال بالكامل